Nurix Therapeutics, Inc. (NRIX) stock

NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30

Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value

$15.48−0.12 (-0.77%)

Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%

Nurix Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Nurix Therapeutics's EV/EBITDA was 2.3× on Nov 11, 2026.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	2.3×	–

Parsed from the XBRL in Nurix Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NRIX.

Revenue growth738.8% · median 15.8%

Operating margin41.3% · median -64.0%

Net margin42.0% · median -51.7%

Advertisement
300 × 250

See a number that looks wrong?